CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
Lenalidomide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02126553
NCT02126553Phase 2Completed
CompareCT.gov

Phase II Study of Lenalidomide Maintenance in Patients With High Risk AML in Remission

M.D. Anderson Cancer Center·interventional·Posted Apr 30, 2014·Updated Nov 14, 2022

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis and Lenalidomide for Alkylating Agent-Related Acute Myeloid Leukemia and Secondary Acute Myeloid Leukemia. Completed, enrolled 29 participants across 1 site.

Detailed Summary

This phase II trial studies how well lenalidomide works in treating patients with acute myeloid leukemia that have had a decrease in or disappearance of signs and symptoms of cancer, although cancer still may be in the body and may be likely to come back or spread. Biological therapies, such as lenalidomide, use substances made from living organisms that may kill cancer cells by blocking blood flow to the cancer and by stimulating white blood cells to kill the cancer cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 30, 2014
Enrollment StartNov 13, 2014
Primary CompletionNov 30, 2021
TodayJul 1, 2026
Enrollment to primary: 7.0 yearsPosted 12.2 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Lenalidomidedrug

Given PO